Q-omics provides the consensus-scored ZNF510 profile across patient tissues and cancer cell-line models. ZNF510 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF510 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ZNF510 RNA expression shows 21,952 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, HNSC, and KIRP as cancer lineages where ZNF510 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF510 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF510 survival associations across molecular data types. ZNF510 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF510 RNA expression–survival associations across cancer types. High ZNF510 expression shows unfavorable associations in ACC, but favorable associations in KIRC, SCLC, THYM, HNSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF510 RNA expression.
This table summarizes ZNF510 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF510. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF510 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher ZNF510 RNA expression in tumor versus normal tissue (log2 FC = +0.579, t-test p < 0.001).
This table shows molecular features associated with ZNF510 in patient tissues and cancer cell lines. In patient samples, ZNF510 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF510 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
